Contemporary Adjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasms - PubMed
5 hours ago
- #pancreatic cancer
- #adjuvant chemotherapy
- #IPMN
- Study evaluates survival benefit of contemporary adjuvant chemotherapy (e.g., GemCap, FOLFIRINOX, mFOLFIRINOX, S-1) after resection for adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMNs).
- Retrospective international cohort of 1321 patients (2017-2023) showed 59.1% received adjuvant chemotherapy, with 72.6% on contemporary regimens.
- After propensity score matching, adjuvant chemotherapy versus no chemotherapy was not associated with improved overall survival (median 82.3 months vs. not reached; P=.58).
- Contemporary regimens versus no chemotherapy showed no significant survival benefit, excluding a mean benefit >4.2 months over 5 years (difference: 1.26 months, 95% CI -1.72 to 4.24).
- Outcomes did not vary by chemotherapy regimen or disease characteristics (e.g., N stage, CA19-9 level), indicating no improved survival with current adjuvant therapies for A-IPMNs.